NCT03873805FDA-approved177Lu-PSMA-617metastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPCcyclophosphamideCyRPT
…ication in mCRPC faces challenges. In a phase 1 clinical trial (NCT03873805) evaluating CAR-T cells targeting Prostate Stem Cell Antigen (P…